US-based Aspen Neuroscience has closed a Series C funding round, raising $115m to further the clinical development of its lead autologous cell therapy candidate, ANPD001, for moderate-to-advanced Parkinson’s disease.
Alvotech and Advanz Pharma have announced the European Commission’s (EC) marketing authorisations for Gobivaz, a biosimilar to Simponi (golimumab), across the European Economic Area (EEA).
Roche has received conditional marketing authorisation from the European Commission (EC) for Lunsumio (mosunetuzumab) subcutaneous (SC) for adults with relapsed or refractory follicular lymphoma (R/R FL) after at least two systemic therapies.
Insmed has received approval from the European Commission (EC) for Brinsupri (brensocatib 25 mg tablets) to treat non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 and above with two or more exacerbations in the year preceding treatment.
Sofinnova Partners has closed its latest Sofinnova Capital XI fund, aimed at supporting early-stage healthcare companies in the US and Europe, at €650m ($750m) above its initial target.
Novartis has opened a 10,000ft² radioligand therapy (RLT) manufacturing facility in Carlsbad in the US state of California, as part of its $23bn investment in the country’s infrastructure up to 2030.
SanegeneBio has formed a worldwide research and licensing partnership with Eli Lilly and Company to develop RNAi [RNA interference] candidates for metabolic diseases.
Alvotech and Advanz Pharma have announced the receipt of marketing authorisations from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for all four formulations of Gobivaz – Alvotech’s biosimilar to Simponi (golimumab).
AmacaThera has entered into an exclusive worldwide licensing agreement with Pacira BioSciences for up to $230m for AMT-143, an investigational long-acting non-opioid anaesthetic.
Naobios and Tokyo Metropolitan Institute of Medical Science (TMIMS) have announced a partnership for the development of a new mpox vaccine using a live-attenuated approach.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.